Cargando…

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study

Patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3–6 months. New treatment modalities are thus urgently needed. Telomerase is expressed in 85–90% of pancreas cancer, and immunogenic telomerase peptides have been characterised. A phase I/II study was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernhardt, S L, Gjertsen, M K, Trachsel, S, Møller, M, Eriksen, J A, Meo, M, Buanes, T, Gaudernack, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360729/ https://www.ncbi.nlm.nih.gov/pubmed/17060934 http://dx.doi.org/10.1038/sj.bjc.6603437

Ejemplares similares

Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.
por: Gjertsen, M. K., et al.
Publicado: (1996)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

2207: A Phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer
por: Ezra Shabason, Jacob, et al.
Publicado: (2018)

Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
por: Ellingsen, Espen Basmo, et al.
Publicado: (2023)

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
por: Ellingsen, Espen Basmo, et al.
Publicado: (2021)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
por: Inderberg-Suso, Else-Marit, et al.
Publicado: (2012)

Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
por: Lutz, Christina M., et al.
Publicado: (2020)

Dose escalation for locally advanced pancreatic cancer: How high can we go?
por: Colbert, Lauren E., et al.
Publicado: (2018)

Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy
por: Jansen, E P M, et al.
Publicado: (2007)

Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial
por: Kovacs, Boldizsar, et al.
Publicado: (2023)

INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a Phase I/II dose escalation study
por: Giordano, Frank A, et al.
Publicado: (2014)

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer
por: Ma, Sung Jun, et al.
Publicado: (2018)

Dose-Escalated Robotic SBRT for Stage I–II Prostate Cancer
por: Meier, Robert
Publicado: (2015)

A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2015)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

The effect of escalating the boost dose for patients with involved resection margin after breast-conserving surgery
por: Park, Sunmin, et al.
Publicado: (2018)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues
por: Sæbøe-Larssen, Stein, et al.
Publicado: (2006)

SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma
por: Ashton, M., et al.
Publicado: (2017)

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
por: van Tilburg, Cornelis M., et al.
Publicado: (2019)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
por: Chaker, A. M., et al.
Publicado: (2016)

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
por: Zhu, Xiaofei, et al.
Publicado: (2022)

Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer
por: Bertholet, Jenny, et al.
Publicado: (2019)

Automated treatment planning as a dose escalation strategy for stereotactic radiation therapy in pancreatic cancer
por: Cilla, Savino, et al.
Publicado: (2020)

Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia
por: Gattoc, Leda, et al.
Publicado: (2016)

Safety and tolerability of escalating cannabinoid doses in healthy cats
por: Kulpa, Justyna E, et al.
Publicado: (2021)

Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial
por: Müller, Arndt-Christian, et al.
Publicado: (2015)

Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study
por: Chen, Jianzhou, et al.
Publicado: (2016)

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy
por: Chapman, Christopher H, et al.
Publicado: (2018)

A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma
por: Budiharto, Tom, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_eahn5pioucusba96o1vk761742